[{"data":1,"prerenderedAt":239},["ShallowReactive",2],{"drug-fluvoxamine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":12,"synonyms":16,"formulations":20,"regimens":52,"contraindications":102,"warnings":140,"renal":141,"monitoring":142,"interactions":143,"review":144,"examples":147,"atc":157,"iran":159,"links":175,"populations":192,"usApproval":234},"fluvoxamine",1,{"fa":7,"en":8},"فلووکسامین","Fluvoxamine","nervous-system",{"fa":11,"en":11},"SSRI",[13],{"name":14,"market":15},"Luvox","US",[17,18,7,19],"luvox","لووکس","فلوکسامین",[21,35,44],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-25","tablet","oral","25 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},25,"mg",false,[15],[32],{"source":33,"section":34},"fda-fluvoxamine","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":41,"refs":42},"tab-50","50 mg tablet (scored)",{"amount":39,"unit":28,"perUnit":23,"scored":40},50,true,[15],[43],{"source":33,"section":34},{"id":45,"form":23,"route":24,"label":46,"concentration":47,"markets":49,"refs":50},"tab-100","100 mg tablet (scored)",{"amount":48,"unit":28,"perUnit":23,"scored":40},100,[15],[51],{"source":33,"section":34},[53,80],{"id":54,"disease":55,"label":56,"population":59,"type":63,"unit":28,"dose":64,"refs":68,"notes":73},"adult","ocd",{"fa":57,"en":58},"OCD — بزرگسال: شروع ۵۰ mg هنگام خواب","OCD — adults: start 50 mg at bedtime",{"minAge":60},{"value":61,"unit":62},18,"year","titration",{"dividedDoses":5,"titration":65},{"start":39,"increment":39,"incrementEveryDays":66,"max":67},4,300,[69,71],{"source":33,"section":70},"2.1",{"source":33,"section":72},"2",[74],{"text":75,"refs":78},{"fa":76,"en":77},"افزایش ۵۰ mg هر ۴ تا ۷ روز؛ حداکثر ۳۰۰ mg\u002Fday؛ بالای ۱۰۰ mg منقسم شود.","Increase by 50 mg every 4–7 days; max 300 mg\u002Fday; divide doses above 100 mg.",[79],{"source":33,"section":72},{"id":81,"disease":55,"label":82,"population":85,"type":63,"unit":28,"dose":89,"refs":91,"notes":95},"peds",{"fa":83,"en":84},"OCD — ۸ تا ۱۷ سال: شروع ۲۵ mg هنگام خواب","OCD — 8–17 y: start 25 mg at bedtime",{"minAge":86,"maxAge":88},{"value":87,"unit":62},8,{"value":61,"unit":62},{"dividedDoses":5,"titration":90},{"start":27,"increment":27,"incrementEveryDays":66,"max":67},[92,94],{"source":33,"section":93},"2.2",{"source":33,"section":72},[96],{"text":97,"refs":100},{"fa":98,"en":99},"افزایش ۲۵ mg هر ۴ تا ۷ روز؛ حداکثر ۲۰۰ mg\u002Fday (۸ تا ۱۱ سال) یا ۳۰۰ mg\u002Fday (۱۲ تا ۱۷ سال)؛ بالای ۵۰ mg منقسم شود.","Increase by 25 mg every 4–7 days; max 200 mg\u002Fday (8–11 y) or 300 mg\u002Fday (12–17 y); divide doses above 50 mg.",[101],{"source":33,"section":72},[103,112,119,130],{"id":104,"severity":105,"text":106,"refs":109},"maoi","block",{"fa":107,"en":108},"همراه یا تا 14 روز پس از MAOI (از جمله لینزولید یا متیلن بلو وریدی).","With or within 14 days of an MAOI (including linezolid or IV methylene blue).",[110],{"source":33,"section":111},"4",{"id":113,"severity":105,"text":114,"refs":117},"ci",{"fa":115,"en":116},"همراه تیزانیدین، تیوریدازین، آلوسترون یا پیموزاید.","With tizanidine, thioridazine, alosetron or pimozide.",[118],{"source":33,"section":111},{"id":120,"severity":105,"rule":121,"text":123,"refs":126},"under-8",{"maxAge":122},{"value":87,"unit":62},{"fa":124,"en":125},"برای زیر ۸ سال تأیید نشده (فقط OCD در ۸ تا ۱۷ سال).","Not approved under 8 years (OCD only, 8–17 y).",[127,129],{"source":33,"section":128},"Boxed Warning",{"source":33,"section":93},{"id":131,"severity":132,"rule":133,"text":135,"refs":138},"suicide","warn",{"maxAge":134},{"value":27,"unit":62},{"fa":136,"en":137},"هشدار جعبه‌ای: افزایش افکار و رفتار خودکشی در کودکان، نوجوانان و جوانان.","Boxed warning: increased suicidal thoughts and behaviour in children, adolescents and young adults.",[139],{"source":33,"section":128},[],[],[],[],{"status":145,"reviewer":146,"date":146},"unverified",null,[148,153],{"regimen":54,"formulation":36,"input":149,"expect":152},{"ageYears":150,"weightKg":151},30,70,{"perDose":39},{"regimen":81,"formulation":22,"input":154,"expect":156},{"ageYears":155,"weightKg":150},10,{"perDose":27},[158],"N06AB08",{"status":160,"forms":161,"refs":170},"registered",[162,166],{"code":163,"en":164,"fa":165},"04708","FLUVOXAMINE MALEATE 100MG TAB","قرص فلووکسامین مالئات ۱۰۰ میلی‌گرم",{"code":167,"en":168,"fa":169},"01827","FLUVOXAMINE MALEATE 50MG TAB","قرص فلووکسامین مالئات ۵۰ میلی‌گرم",[171],{"source":172,"section":173,"url":174},"darooyab-generic","G-586\u002FFluvoxamine","https:\u002F\u002Fwww.darooyab.ir\u002FG-586\u002FFluvoxamine",[176,180,184,187,190],{"kind":177,"url":178,"label":179},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=075902","ANDA075902",{"kind":181,"url":182,"label":183},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=6eeb14df-6fcf-a737-5359-5744eb4accea","FDA Fluvoxamine",{"kind":185,"url":186,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa695004.html",{"kind":188,"url":189,"label":158},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N06AB08",{"kind":191,"url":174,"label":8},"darooyab",{"pregnancy":193,"lactation":202,"pediatric":210,"geriatric":218,"reproductive":226},{"level":194,"text":195,"quote":198,"refs":199},"caution",{"fa":196,"en":197},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Based on data from published observational studies, exposure to SSRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions ( 5.10 ) and Clinical Considerations].",[200],{"source":33,"section":201},"8.1",{"level":194,"text":203,"quote":206,"refs":207},{"fa":204,"en":205},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Data from published literature report the presence of fluvoxamine is in human milk (see Data).",[208],{"source":33,"section":209},"8.2",{"level":211,"text":212,"quote":215,"refs":216},"avoid",{"fa":213,"en":214},"هشدار جعبه‌ای برچسب درباره کودکان.","Boxed warning in the label about children.","Fluvoxamine maleate tablets are not approved for use in pediatric patients except for patients with obsessive compulsive disorder (OCD) [see Warnings and Precautions ( 5.1 )] .",[217],{"source":33,"section":128},{"level":194,"text":219,"quote":222,"refs":223},{"fa":220,"en":221},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","… ly significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions ( 5.13 )] .",[224],{"source":33,"section":225},"8.5",{"level":194,"text":227,"quote":230,"refs":231},{"fa":228,"en":229},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Infertility Animal findings suggest fertility may be impaired while taking fluvoxamine [see Nonclinical Toxicology ( 13.1 )].",[232],{"source":33,"section":233},"8.3",{"kind":235,"refs":236,"id":179},"ANDA",[237],{"source":33,"section":238},"SPL approval \u002F marketing category",1792191877573]